Clinical trial · Interventional
Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma
NCT03722355CI-TRIAL-00041573completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hyperfractionated radiation therapy (RT) to 72.0 Gy with BCNU will be compared to conventional radiation therapy to 60.0 Gy with BCNU to determine if hyperfractionated RT can improve the median survival time of adults with supratentorial malignant gliomas.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Astrocytoma | Astrocytoma | CURATED_BROADER | 0.80 |
| Glioblastoma Multiforme | Glioblastoma | CURATED_BROADER | 0.80 |
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carmustine | Drug | Carmustine | ALIAS |
| Conventional RT | Radiation | — | UNRESOLVED |
| Hyperfractionated RT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm 1: Conventional RT + Carmustine
- description
- Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles
- interventionNames
- Radiation: Conventional RT
- Drug: Carmustine
- type
- EXPERIMENTAL
- label
- Arm 2: Hyperfractionated RT + Carmustine
- description
- Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles
- interventionNames
- Radiation: Hyperfractionated RT
- Drug: Carmustine
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathologically confirmed glioblastoma multiforme (with areas of necrosis), malignant astrocytoma and astrocytoma with foci of anaplasia * Karnofsky Performance Score ≥ 60 * Absolute Neutrophil count ≥ 1,500 * Platelets ≥ 100,000 * BUN ≤ 25 * Creatinine ≤ 1.5 * Bilirubin ≤ 2.0 * Hemoglobin ≥ 10 gm * SGOT \< 2 x upper limit of normal * SGPT \< 2 x upper limit of normal Exclusion Criteria: * No prior radiation to the head or neck area, chemotherapy or radiosensitizer * No malignancy with the past five years except non-melanomatous skin cancer or carcinoma in-situ of the cervix
References
Publications (1)
- DERIVEDBrown MH, Cherng HR, Assif JW, Sun K, Mishra MV. Conditional Survival Estimates for Malignant Glioma Patients: Secondary Analysis of RTOG 9006. Am J Clin Oncol. 2026 Jun 1;49(6):264-267. doi: 10.1097/COC.0000000000001296. Epub 2026 Mar 19. PMID 41850328